Axonics Modulation Technologies has added $20.5 million to its Series C, bringing the round to $35 million.
The Irvine, California company previously closed $14.5 million of its Series C in early May.
Axonics has developed the first rechargeable Sacral Neuromodulation (r-SNM) system to treat urinary and bowel dysfunction.
The company will use the the new financing to conduct a pivotal clinical study in patients with overactive bladders to gain U.S. FDA approval. The study is expected to begin…
Axonics Modulation Technologies has added $20.5 million to its Series C, bringing the round to $35 million.
The Irvine, California company previously closed $14.5 million of its Series C in early May.
Axonics has developed the first rechargeable Sacral Neuromodulation (r-SNM) system to treat urinary and bowel dysfunction.
The company will use the the new financing to conduct a pivotal clinical study in patients with overactive bladders to gain U.S. FDA approval. The study is expected to begin…